InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of InspireMD (NYSE:NSPR) in a report published on Thursday morning. The firm issued a sell rating on the stock.

Separately, Lake Street Capital started coverage on shares of InspireMD in a report on Wednesday, December 11th. They set a “buy” rating and a $5.00 target price on the stock.

InspireMD Price Performance

NSPR stock opened at $2.62 on Thursday. The firm has a 50 day simple moving average of $2.80 and a two-hundred day simple moving average of $2.74. The stock has a market cap of $68.33 million, a PE ratio of -3.49 and a beta of 1.00. InspireMD has a one year low of $1.81 and a one year high of $3.42.

InspireMD (NYSE:NSPR) last announced its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.04. InspireMD had a negative net margin of 413.96% and a negative return on equity of 69.42%. The company had revenue of $1.81 million during the quarter, compared to analyst estimates of $1.74 million. During the same period in the previous year, the business earned ($0.15) earnings per share. On average, research analysts expect that InspireMD will post -0.79 EPS for the current fiscal year.

Hedge Funds Weigh In On InspireMD

Institutional investors and hedge funds have recently bought and sold shares of the stock. Affiance Financial LLC bought a new stake in InspireMD in the third quarter valued at approximately $492,000. Parkman Healthcare Partners LLC bought a new stake in InspireMD during the 3rd quarter valued at $279,000. Finally, Legato Capital Management LLC purchased a new stake in InspireMD during the 4th quarter valued at $47,000. 44.78% of the stock is currently owned by institutional investors.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.